Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings
Samsung Biologics disclosed a $262 million biologics manufacturing contract running through 2033. The work will be produced at Songdo, South Korea. The deal lifts Samsung Biologics’ cumulative contract value above $21.9 billion, per BioPharm International.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key facts, context, and what it means, in one minute.
Key takeaways
Duration is the headline: Samsung Biologics’ new $262 million contract with an unnamed European pharma company runs through Dec. 31, 2033, a long-dated commitment for the Songdo site (per BioPharm International).
CDMO selection is drifting from “price per batch” to “operating model”: Samsung Biologics executives have framed CDMOs as extensions of sponsor operations, which raises expectations for transparency, change control, and schedule flexibility (per BioPharm International).
Get featured
Want to get featured in MarketScale Sciences?
Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.
Samsung Biologics reported a $262 million manufacturing contract with a European pharmaceutical company that was not identified, extending through 2033. A regulatory filing cited by Contract Pharma and BioPharm International says the project will be carried out at the company’s Songdo facility in South Korea.
For biopharma operations leaders, the headline isn’t the customer name, it’s the duration. The agreement runs through December 31, 2033, according to BioPharm International.
What the contract actually says, and what it implies for capacity strategy
BioPharm International reported the agreement is valued at about $262 million (350.8 billion won) and runs through Dec. 31, 2033, with confidentiality provisions covering the customer and product. Contract Pharma likewise reported the deal was disclosed via a securities filing under Korean market rules and that product details will remain confidential.
BioPharm International tied the contract to Samsung Biologics’ broader utilization story, noting the deal pushes the company’s cumulative contract value since founding past $21.9 billion.
CDMO oversight is getting closer to “operate like a site you own”
A point in BioPharm International’s report is especially relevant for quality and supply leaders: Kasper Øland, vice president of sales execution at Samsung Biologics, said clients are more often looking for a CDMO that operates like part of their own operations, providing more predictability, transparency, and flexibility on timelines, according to BioPharm International.
Regulatory signals in the background: AI leadership at FDA and combination product friction
Separate from the Samsung Biologics deal, Regulatory Focus reported that FDA named permanent leaders for CDER and CBER and named a deputy commissioner for technology and artificial intelligence.
Regulatory Focus also published a RAPS Convergence 2026 speaker interview with Sujith Kallur Mallikarjuna, associate director, regulatory affairs at BD, about combination products, according to Regulatory Focus.
Where this lands in 2027, 2030 sourcing and validation plans
- Confirm where the work will be executed. BioPharm International and Contract Pharma reported that production will take place at Samsung Biologics’ Songdo, South Korea, site.
- Confirm what confidentiality covers. BioPharm International reported that the client’s identity and the product were not disclosed under business confidentiality provisions.
Sources
- Samsung Biologics signs $262M manufacturing deal with European pharma company ↗ · Contract Pharma
- Samsung Biologics signs $262M biologics manufacturing deal with undisclosed European pharma company ↗ · BioPharm International
- Samsung Biologics signs $262 million manufacturing agreement with European pharma firm ↗ · Genetic Engineering and Biotechnology News
- FDA names permanent CDER, CBER directors, new deputy commissioner for AI ↗ · Regulatory Focus
- Sujith Kallur Mallikarjuna wants to change the way we talk about combination products ↗ · Regulatory Focus
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.
